close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Kodu・Aktsiate loetelu・Nektar Therapeutics
Search

Nektar Therapeutics

Suletud

84.6 0.91

Tugev "osta" hinnang

Hinna uuendus 17. apr 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

83.92

Max

86.86

Põhinäitajad

By Trading Economics

Sissetulek

-557K

-36M

Müük

10M

22M

Aktsiakasum

-1.29

Kasumimarginaal

-165.447

Töötajad

63

EBITDA

10M

-19M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+36.41% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

373M

2.3B

Eelmine avamishind

83.69

Eelmine sulgemishind

84.6

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

0.5949 / 0.7406 Toetus ja vastupanu

Nektar Therapeutics Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. apr 2026, 20:26 UTC

Omandamised, ülevõtmised, äriostud

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

DJ

Loe

17. apr 2026, 18:15 UTC

Uudisväärsed sündmused

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

DJ

Loe

17. apr 2026, 16:49 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

DJ

Loe

17. apr 2026, 16:49 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

DJ

Loe

17. apr 2026, 22:58 UTC

Tulu

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

DJ

Loe

17. apr 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

DJ

Loe

17. apr 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

17. apr 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

DJ

Loe

17. apr 2026, 20:52 UTC

Tulu

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

DJ

Loe

17. apr 2026, 20:50 UTC

Market Talk
Tulu
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

17. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Loe

17. apr 2026, 20:29 UTC

Tulu

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

DJ

Loe

17. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

UCB to Buy Neurona Therapeutics for Up to $1.15B

DJ

Loe

17. apr 2026, 19:34 UTC

Market Talk
Tulu
Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

DJ

Loe

17. apr 2026, 19:34 UTC

Market Talk
Tulu
Omandamised, ülevõtmised, äriostud

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

DJ

Loe

17. apr 2026, 19:31 UTC

Market Talk
Uudisväärsed sündmused

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

DJ

Loe

17. apr 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

DJ

Loe

17. apr 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

DJ

Loe

17. apr 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

DJ

Loe

17. apr 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

DJ

Loe

17. apr 2026, 18:57 UTC

Uudisväärsed sündmused

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

DJ

Loe

17. apr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

DJ

Loe

17. apr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

UCB 2026 Rev Guidance Unchanged

DJ

Loe

17. apr 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

DJ

Loe

17. apr 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

DJ

Loe

17. apr 2026, 18:14 UTC

Market Talk
Uudisväärsed sündmused

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

DJ

Loe

17. apr 2026, 18:00 UTC

Uudisväärsed sündmused

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

DJ

Loe

17. apr 2026, 18:00 UTC

Uudisväärsed sündmused

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

DJ

Loe

17. apr 2026, 17:31 UTC

Market Talk
Uudisväärsed sündmused

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

DJ

Loe

17. apr 2026, 17:26 UTC

Market Talk
Tulu

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Nektar Therapeutics Prognoos

Hinnasiht

By TipRanks

36.41% tõus

12 kuu keskmine prognoos

Keskmine 114.57 USD  36.41%

Kõrge 151 USD

Madal 68 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Nektar Therapeutics 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Põhineb 8 analüütiku instrumendi Nektar Therapeutics aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.5949 / 0.7406Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Strong Bearish Evidence

All events are bearish.

Pikk perspektiiv

Bearish Evidence

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Muud aktsiad sektorist

MDT

Medtronic PLC

86.08

↑ +0.56%

A

Agilent Technologies Inc

121.65

↑ +2.99%

VEEV

Veeva Systems Inc

167.9

↑ +0.35%

HQY

HealthEquity Inc

85.93

↑ +1.81%

NEOG

Neogen Corp

9.5

↑ +2.81%
help-icon Live chat